[Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe].

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.Annals of the rheumatic diseases · 2011
   Pooled it
2. [ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area].Zeitschrift fur Rheumatologie · 2013
   Article
3. [Advice for patients diagnosed with ankylosing spondylitis: results of a representative patient survey in Germany].Zeitschrift fur Rheumatologie · 2011
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as